American Journal of Clinical Dermatology

, Volume 13, Issue 3, pp 191–211

Etiology and Management of Pyoderma Gangrenosum

A Comprehensive Review
Review Article

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful, necrotic ulceration. It typically affects patients in the third to sixth decades of life, with almost equal incidence in men and women. PG occurs most frequently on the lower extremities. Five clinical variants are currently recognized: classic, bullous, pustular, vegetative, and peristomal types. Half of PG cases are seen in association with systemic disease. Mimickers include infection, vascular insufficiency ulcers, systemic vasculitides, autoimmune disease, cancer, and exogenous tissue injury, among others. PG is often a diagnosis of exclusion, as there are no specific laboratory or histopathologic findings to confirm the diagnosis. PG thus presents many clinical challenges: it is difficult to diagnose, is frequently misdiagnosed, and often requires a work-up for underlying systemic disease. Successful management of PG typically requires multiple modalities to reduce inflammation and optimize wound healing, in addition to treatment of any underlying diseases. Prednisone and cyclosporine have been mainstays of systemic treatment for PG, although increasing evidence supports the use of biologic therapies, such as tumor necrosis factor-a inhibitors, for refractory cases of PG. Here, we review the clinical presentation and pathophysiology of PG, as well as its associated conditions, diagnostic work-up, and management.

References

  1. 1.
    Brocq L. Nouvelle contribution a l’etude du phagedenisme geometrique. Ann Dermatol Syphil 1916; 6 (1): 1–39Google Scholar
  2. 2.
    Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma (ecthyma) gangrenosum. Arch Dermatol 1930; 22: 655–80Google Scholar
  3. 3.
    Powell FC, Schroeter AL, Su WP, et al. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985 May; 55 (217): 173–86Google Scholar
  4. 4.
    Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996 Mar; 34 (3): 395–409; quiz 410-412Google Scholar
  5. 5.
    Powell FC, Schroeter AL, Su WP, et al. Pyoderma gangrenosum and sarcoidosis. Arch Dermatol 1984 Jul; 120 (7): 959–60Google Scholar
  6. 6.
    Körber A, Klode J, Al-Benna S, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges 2011 Feb; 9 (2): 116–21PubMedGoogle Scholar
  7. 7.
    Su WPD, Davis MDP, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004 Nov; 43 (11): 790–800Google Scholar
  8. 8.
    Vidal D, Puig L, Gilaberte M, et al. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat 2004 Jun; 15 (3): 146–52Google Scholar
  9. 9.
    Powell FC, Perry HO. Pyoderma gangrenosum in childhood. Arch Dermatol 1984 Jun; 120 (6): 757–61Google Scholar
  10. 10.
    Miserocchi E, Modorati G, Foster CS, et al. Ocular and extracutaneous involvement in pyoderma gangrenosum. Ophthalmology 2002 Oct; 109 (10): 1941–3Google Scholar
  11. 11.
    Krüger S, Piroth W, Amo Takyi B, et al. Multiple aseptic pulmonary nodules with central necrosis in association with pyoderma gangrenosum. Chest 2001 Mar; 119 (3): 977–8Google Scholar
  12. 12.
    Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin Dermatol 2000 Jun; 18 (3): 339–47Google Scholar
  13. 13.
    Marie I, Levesque H, Joly P, et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol 2001 Jan; 44 (1): 137–9Google Scholar
  14. 14.
    Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988 Mar; 18 (3): 511–21Google Scholar
  15. 15.
    Zivanović D, Tanasilović S, Skiljević D, et al. Atypical pyoderma gangrenosum in a patient with osteomyelofibrosis. Vojnosanit Pregl 2007 Nov; 64 (11): 787–9Google Scholar
  16. 16.
    O’Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 1978 Jul; 114 (7): 1061–4Google Scholar
  17. 17.
    Cairns BA, Herbst CA, Sartor BR, et al. Peristomal pyoderma gangrenosum and inflammatory bowel disease. Arch Surg 1994 Jul; 129 (7): 769–72Google Scholar
  18. 18.
    Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000 Sep 27; 284 (12): 1546–8Google Scholar
  19. 19.
    Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000 May; 135 (5): 564–8; discussion 568-9Google Scholar
  20. 20.
    Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 1972 Dec; 106 (6): 901–5Google Scholar
  21. 21.
    Dean SM, Zirwas M. A second case of sunitinib-associated pyoderma gangrenosum. J Clin Aesthet Dermatol 2010 Aug; 3 (8): 34–5Google Scholar
  22. 22.
    Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol 2006 Nov; 55 (5 Suppl.): S107–8Google Scholar
  23. 23.
    ten Freyhaus K, Homey B, Bieber T, et al. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol 2008 Jul; 159 (1): 242–3Google Scholar
  24. 24.
    Tinoco MP, Tamler C, Maciel G, et al. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol 2008 Sep; 47 (9): 953–6Google Scholar
  25. 25.
    Rostenberg Jr A. The Shwartzman phenomenon: a review with a consideration of some possible dermatological manifestations. Br J Dermatol 1953 Nov; 65 (11): 389–405Google Scholar
  26. 26.
    Shwartzman G. Concerning the specificity and nature of the phenomenon of local skin reactivity to various bacterial filtrates. J Exp Med 1930 Mar 31; 51 (4): 571–83Google Scholar
  27. 27.
    Vignon-Pennamen MD, Wallach D. Cutaneous manifestations of neutrophilic disease: a study of seven cases. Dermatologica 1991; 183 (4): 255–64PubMedGoogle Scholar
  28. 28.
    Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998 Aug; 111 (2): 259–68Google Scholar
  29. 29.
    Parren LJMT, Nellen RGL, van Marion AMW, et al. Penile pyoderma gangrenosum: successful treatment with colchicine. Int J Dermatol 2008 Nov; 47 Suppl. 1: 7–9Google Scholar
  30. 30.
    Brown RE, Lay L, Graham D. Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg Br 1993 Feb; 18 (1): 119–21Google Scholar
  31. 31.
    Galeazzi M, Gasbarrini G, Ghirardello A, et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006 Feb; 24 (1 Suppl. 40): S79–85Google Scholar
  32. 32.
    Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009 Sep; 23 (9): 1008–17Google Scholar
  33. 33.
    Weenig RH, Davis MDP, Dahl PR, et al. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002 Oct 31; t347 (18): 1412–8Google Scholar
  34. 34.
    Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010 Nov; 146 (11): 1265–70Google Scholar
  35. 35.
    Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. Epub 2011 Jul 9Google Scholar
  36. 36.
    al-Rimawi HS, Abuekteish FM, Daoud AS, et al. Familial pyoderma gangrenosum presenting in infancy. Eur J Pediatr 1996 Sep; 155 (9): 759–62Google Scholar
  37. 37.
    Shands JW, Flowers FP, Hill HM, et al. Pyoderma gangrenosum in a kindred: precipitation by surgery or mild physical trauma. J Am Acad Dermatol 1987 May; 16 (5 Pt 1): 931–4Google Scholar
  38. 38.
    Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997 Jul; 72 (7): 611–5Google Scholar
  39. 39.
    Yeon HB, Lindor NM, Seidman JG, et al. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 2000 Apr; 66 (4): 1443–8Google Scholar
  40. 40.
    Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002 Apr 15; 11 (8): 961–9Google Scholar
  41. 41.
    Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003 Nov 11; 100 (23): 13501–6Google Scholar
  42. 42.
    Kluin-Nelemans JC, Ramselaar CG. Hepatic abscesses, pyoderma gangrenosum-like dermatitis and IgA immune complexes; a presentation of chronic granulomatous disease in an adult. Neth J Med 1982; 25 (4): 100–4PubMedGoogle Scholar
  43. 43.
    Hinze CH, Lucky AW, Bove KE, et al. Leukocyte adhesion deficiency type 1 presenting with recurrent pyoderma gangrenosum and flaccid scarring. Pediatr Dermatol 2010 Oct; 27 (5): 500–3Google Scholar
  44. 44.
    Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol 2000 Jul; 143 (1): 154–6Google Scholar
  45. 45.
    Oka M, Berking C, Nesbit M, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000 Apr; 80 (4): 595–604Google Scholar
  46. 46.
    Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009 Nov; 161 (5): 1199–201Google Scholar
  47. 47.
    Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000 Jan; 79 (1): 37–46Google Scholar
  48. 48.
    von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with followup. Br J Dermatol 1997 Dec; 137 (6): 1000–5Google Scholar
  49. 49.
    Bhat RM, Nandakishore B, Sequeira FF, et al. Pyoderma gangrenosum: an Indian perspective. Clin Exp Dermatol 2011 Apr; 36 (3): 242–7PubMedGoogle Scholar
  50. 50.
    Altieri M, Vaziri K, Orkin BA. Topical tacrolimus for parastomal pyoderma gangrenosum: a report of two cases. Ostomy Wound Manage 2010 Sep; 56 (9): 56–9Google Scholar
  51. 51.
    Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011 Jan; 106 (1): 110–9Google Scholar
  52. 52.
    Wasmuth HH, Tranø G, Endreseth BH, et al. Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis. J Gastrointest Surg 2010 Jul; 14 (7): 1099–104Google Scholar
  53. 53.
    Yüksel I, Ataseven H, Başar O, et al. Peripheral arthritis in the course ofinflammatory bowel diseases. Dig Dis Sci 2011 Jan; 56 (1): 183–7Google Scholar
  54. 54.
    Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol 2009 Jul; 145 (7): 781–5Google Scholar
  55. 55.
    Funayama Y, Kumagai E, Takahashi K-I, et al. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosumin inflammatory bowel disease. Dis Colon Rectum 2009 Feb; 52 (2): 311–4Google Scholar
  56. 56.
    Moravvej H, Razavi GM, Farshchian M, et al. Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: a retrospective study. Indian J Dermatol Venereol Leprol 2008 Dec; 74 (6): 607–10Google Scholar
  57. 57.
    McCallum DI, Kinmont PD. Dermatological manifestations of Crohn’s disease. Br J Dermatol 1968 Jan; 80 (1): 1–8Google Scholar
  58. 58.
    Perry HO. Pyoderma gangrenosum. South Med J 1969 Aug; 62 (8): 899–908Google Scholar
  59. 59.
    Johnson ML, Wilson HT. Skin lesions in ulcerative colitis. Gut 1969 Apr; 10 (4): 255–63PubMedGoogle Scholar
  60. 60.
    Hickman JG, Lazarus GS. Pyoderma gangrenosum: a reappraisal of associated systemic diseases. Br J Dermatol 1980 Feb; 102 (2): 235–7Google Scholar
  61. 61.
    Hong J-B, Su Y-N, Chiu H-C. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. J Am Acad Dermatol 2009 Sep; 61 (3): 533–5Google Scholar
  62. 62.
    Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum: review of 21 cases. Arch Dermatol 1989 Jan; 125 (1): 57–64Google Scholar
  63. 63.
    Tjandra JJ, Hughes LE. Parastomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum 1994 Sep; 37 (9): 938–42Google Scholar
  64. 64.
    Mlika RB, Riahi I, Fenniche S, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol 2002 Feb; 41 (2): 65–8Google Scholar
  65. 65.
    Shankar S, Sterling JC, Rytina E. Pustular pyoderma gangrenosum. Clin Exp Dermatol 2003 Nov; 28 (6): 600–3Google Scholar
  66. 66.
    Hasselmann DO, Bens G, Tilgen W, et al. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007 Jul; 5 (7): 560–4Google Scholar
  67. 67.
    Seitz CS, Berens N, Brücker E-B, et al. Leg ulceration in rheumatoid arthritis: an underreported multicausal complication with considerable morbidity. Analysis of thirty-six patients and review of the literature. Dermatology (Basel) 2010; 220 (3): 268–73Google Scholar
  68. 68.
    English JS, Fenton DA, Barth J, et al. Pyoderma gangrenosum and leucocytoclastic vasculitis in association with rheumatoid arthritis: a report of two cases. Clin Exp Dermatol 1984 May; 9 (3): 270–6Google Scholar
  69. 69.
    Holt PJ, Davies MG, Saunders KC, et al. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) 1980 Mar; 59 (2): 114–33Google Scholar
  70. 70.
    Stolman LP, Rosenthal D, Yaworsky R, et al. Pyoderma gangrenosum and rheumatoid arthritis. Arch Dermatol 1975 Aug; 111 (8): 1020–3Google Scholar
  71. 71.
    Duguid CM, O’Loughlin S, Otridge B, et al. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol 1993; 34 (1): 17–22PubMedGoogle Scholar
  72. 72.
    Hay CR, Messenger AG, Cotton DW, et al. Atypical bullous pyoderma gangrenosum associated with myeloid malignancies. J Clin Pathol 1987 Apr; 40 (4): 387–92Google Scholar
  73. 73.
    Jacobs P, Palmer S, Gordon-Smith EC. Pyoderma gangrenosum in myelodysplasia and acute leukaemia. Postgrad Med J 1985 Aug; 61 (718): 689–94Google Scholar
  74. 74.
    Powell FC, Schroeter AL, Su WP, et al. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol 1983 Jun; 119 (6): 468–72Google Scholar
  75. 75.
    Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978 May; 64 (5): 814–26Google Scholar
  76. 76.
    Tallon B, Rademaker M, Parkinson G, et al. Cavitary pyoderma gangrenosum treated with local infusion of corticosteroid. J Am Acad Dermatol 2007 Apr; 56 (4): 696–9Google Scholar
  77. 77.
    Masatlioğ lu SP, Göktay F, Mansur AT, et al. Systemic lupus erythematosus presenting as pyoderma gangrenosum in two cases. Rheumatol Int 2009 May; 29 (7): 837–40Google Scholar
  78. 78.
    Kole AK, Ghosh A. Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol 2009; 54 (2): 132–6PubMedGoogle Scholar
  79. 79.
    Livideanu C, Lipsker D, Paul C, et al. Pyoderma gangrenosum as initial manifestation of Graves’ disease. Clin Exp Dermatol 2006 Sep; 31 (5): 659–61Google Scholar
  80. 80.
    Byrne JP, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis: report of two cases. Arch Dermatol 1976 Sep; 112 (9): 1297–301Google Scholar
  81. 81.
    Fonseka HFS, Ekanayake SMB, Dissanayake M. Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study. Int Wound J 2010 Dec; 7 (6): 519–23Google Scholar
  82. 82.
    Paller AS, Sahn EE, Garen PD, et al. Pyoderma gangrenosum in pediatric acquired immunodeficiency syndrome. J Pediatr 1990 Jul; 117 (1 Pt 1): 63–6Google Scholar
  83. 83.
    Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008 Sep; 87 (5): 281–93Google Scholar
  84. 84.
    Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004 Feb; 6 (2): 88–90Google Scholar
  85. 85.
    Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007 Oct; 46 (10): 1095–9PubMedGoogle Scholar
  86. 86.
    Ayestaray B, Dudrap E, Chartaux E, et al. Necrotizing pyoderma gangrenosum: an unusual differential diagnosis of necrotizing fasciitis. J Plast Reconstr Aesthet Surg 2010 Aug; 63 (8): e655–8Google Scholar
  87. 87.
    Callen JP, Dubin HV, Gehrke CF. Recurrent pyoderma gangrenosum and agnogenic myeloid metaplasia. Arch Dermatol 1977 Nov; 113 (11): 1585–6Google Scholar
  88. 88.
    Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders: atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 1983 Nov; 9 (5): 751–8Google Scholar
  89. 89.
    Stanojevic N, Mai C. It starts with a dog scratch. J Hosp Med 2010 Oct; 5 (8): 494–5Google Scholar
  90. 90.
    Ryu J, Naik H, Yang FC, et al. Pyoderma gangrenosum presenting with leukemoid reaction: a report of 2 cases. Arch Dermatol 2010 May; 146 (5): 568–9Google Scholar
  91. 91.
    Koester G, Tarnower A, Levisohn D, et al. Bullous pyoderma gangrenosum. J Am Acad Dermatol 1993 Nov; 29 (5 Pt 2): 875–8Google Scholar
  92. 92.
    Alibhai SMH, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 2009 Jul 1; 115 (13): 2903–11Google Scholar
  93. 93.
    Fox LP, Geyer AS, Husain S, et al. Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia. Leuk Lymphoma 2006 Jan; 47 (1): 147–50Google Scholar
  94. 94.
    Rafael MR, Fernandes CM, Machado JM, et al. Pyoderma gangrenosum or leukaemia cutis? J Eur Acad Dermatol Venereol 2003 Jul; 17 (4): 449–51Google Scholar
  95. 95.
    Török L, Kirschner A, Gurzó M, et al. Bullous pyoderma gangrenosum as a manifestation of leukemia cutis. Eur J Dermatol 2000 Aug; 10 (6): 463–5Google Scholar
  96. 96.
    Nguyen KH, Miller JJ, Helm KF. Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum. Int J Dermatol 2003 Feb; 42 (2): 84–94Google Scholar
  97. 97.
    Hemp L, Hall S. Pyoderma gangrenosum: from misdiagnosis to recognition, a personal perspective. J Wound Care 2009 Dec; 18 (12): 521–6Google Scholar
  98. 98.
    Barr KL, Chhatwal HK, Wesson SK, et al. Pyoderma gangrenosum masquerading as necrotizing fasciitis. Am J Otolaryngol 2009 Aug; 30 (4): 273–6Google Scholar
  99. 99.
    Mahajan AL, Ajmal N, Barry J, et al. Could your case of necrotising fascitis be pyoderma gangrenosum? Br J Plast Surg 2005 Apr; 58 (3): 409–12Google Scholar
  100. 100.
    Su WP, Schroeter AL, Perry HO, et al. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986 Oct; 13 (5): 323–30Google Scholar
  101. 101.
    Powell FC, Schroeter AL, Perry HO, et al. Direct immunofluorescence in pyoderma gangrenosum. Br J Dermatol 1983 Mar; 108 (3): 287–93Google Scholar
  102. 102.
    Wenzel J, Gerdsen R, Phillipp-Dormston W, et al. Topical treatment of pyoderma gangraenosum. Dermatology (Basel) 2002; 205 (3): 221–3Google Scholar
  103. 103.
    Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010 Apr; 62 (4): 646–54Google Scholar
  104. 104.
    Kean J. The effects of smoking on the wound healing process. J Wound Care 2010 Jan; 19 (1): 5–8Google Scholar
  105. 105.
    Wolf R, Wolf D, Ruocco V. The benefits of smoking in skin diseases. Clin Dermatol 1998 Oct; 16 (5): 641–7Google Scholar
  106. 106.
    Patel GK, Rhodes JR, Evans B, et al. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J Dermatolog Treat 2004 Apr; 15 (2): 122–5Google Scholar
  107. 107.
    Fonder MA, Lazarus GS, Cowan DA, et al. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008 Feb; 58 (2): 185–206Google Scholar
  108. 108.
    Gottrup F, Karlsmark T. Leg ulcers: uncommon presentations. Clin Dermatol 2005 Dec; 23 (6): 601–11Google Scholar
  109. 109.
    Siegel DM. Contact sensitivity and recalcitrant wounds. Ostomy Wound Manage 2000 Jan; 46 (1A Suppl.): 65S–74S; quiz 75S-76SGoogle Scholar
  110. 110.
    Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996 Jun; 34 (6): 1047–60Google Scholar
  111. 111.
    Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol 1992 Aug; 31 (8): 574–7Google Scholar
  112. 112.
    Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum. Med J Malaysia 2008 Mar; 63 (1): 51–4Google Scholar
  113. 113.
    Campbell S, Cripps S, Jewell DP. Therapy insight: pyoderma gangrenosumold disease, new management. Nat Clin Pract Gastroenterol Hepatol 2005 Dec; 2 (12): 587–94Google Scholar
  114. 114.
    Chiba T, Isomura I, Suzuki A, et al. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005 Mar; 32 (3): 199–203Google Scholar
  115. 115.
    Le Cleach L, Moguelet P, Perrin P, et al. Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol 2011 Jan; 147 (1): 101–3Google Scholar
  116. 116.
    Theissen U, Luger TA, Schwarz T. Successful topical administration of cyclosporin A in pyoderma gangraenosum [in German]. Hautarzt 1996 Feb; 47 (2): 132–5Google Scholar
  117. 117.
    Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in themanagement of peristomal pyoderma gangrenosum. J Dermatolog Treat 2001 Mar; 12 (1): 13–7Google Scholar
  118. 118.
    Ghislain P-D, De Decker I, Lachapelle J-M. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol 2004 May; 150 (5): 1052–3Google Scholar
  119. 119.
    Sanders CJ, Hulsmans RF. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993 Apr; 51 (4): 262–4Google Scholar
  120. 120.
    Braun-Falco M, Stock K, Ring J, et al. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum. Br J Dermatol 2002 Oct; 147 (4): 829–31Google Scholar
  121. 121.
    Tamir A, Landau M, Brenner S. Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology (Basel) 1996; 192 (3): 252–4Google Scholar
  122. 122.
    Powell FC, O’Kane M. Management of pyoderma gangrenosum. Dermatol Clin 2002 Apr; 20 (2): 347–55, viiiGoogle Scholar
  123. 123.
    Tsele E, Yu RC, Chu AC. Pyoderma gangrenosum: response to topical nitrogen mustard. Clin Exp Dermatol 1992 Nov; 17 (6): 437–40Google Scholar
  124. 124.
    Moschella SL. Pyoderma gangrenosum: a patient successfully treated with intralesional injections of steroid. Arch Dermatol 1967 Jan; 95 (1): 121–3Google Scholar
  125. 125.
    Goldstein F, Krain R, Thornton JJ. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 1985 Dec; 7 (6): 499–501Google Scholar
  126. 126.
    Mrowietz U, Christophers E. Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br J Dermatol 1991 Nov; 125 (5): 499-1Google Scholar
  127. 127.
    Ma G, Jones G, MacKay G. Pyoderma gangrenosum: a great marauder. Ann Plast Surg 2002 May; 48 (5): 546–52; discussion 552-553Google Scholar
  128. 128.
    Classen DA, Thomson C. Free flap coverage of pyoderma gangrenosum leg ulcers. J Cutan Med Surg 2002 Aug; 6 (4): 327–31Google Scholar
  129. 129.
    Límová M, Mauro T. Treatment of pyoderma gangrenosum with cultured keratinocyte autografts. J Dermatol Surg Oncol 1994 Dec; 20 (12): 833–6Google Scholar
  130. 130.
    Niezgoda JA, Cabigas EB, Allen HK, et al. Managing pyoderma gangrenosum: a synergistic approach combining surgical débridement, vacuumassisted closure, and hyperbaric oxygen therapy. Plast Reconstr Surg 2006 Feb; 117 (2): 24e–8eGoogle Scholar
  131. 131.
    Kaddoura IL, Amm C. A rationale for adjuvant surgical intervention in pyoderma gangrenosum. Ann Plast Surg 2001 Jan; 46 (1): 23–8Google Scholar
  132. 132.
    Long CC, Jessop J, Young M, et al. Minimizing the risk of post-operative pyoderma gangrenosum. Br J Dermatol 1992 Jul; 127 (1): 45–8Google Scholar
  133. 133.
    Rozen SM, Nahabedian MY, Manson PN. Management strategies for pyoderma gangrenosum: case studies and review of literature. Ann Plast Surg 2001 Sep; 47 (3): 310–5Google Scholar
  134. 134.
    Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, et al. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology (Basel) 2004; 209 (3): 233–6Google Scholar
  135. 135.
    Fukuhara K, Urano Y, Kimura S, et al. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998 Sep; 139 (3): 556–8Google Scholar
  136. 136.
    Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986 Oct; 81 (10): 988–9Google Scholar
  137. 137.
    Joshi A, Mamta. Behçet’s syndrome with pyoderma-gangrenosum-like lesions treated successfully with dapsone monotherapy. J Dermatol 2004 Oct; 31 (10): 806–10Google Scholar
  138. 138.
    Handler MZ, Hamilton H, Aires D. Treatment of peristomal pyoderma gangrenosum with topical crushed dapsone. J Drugs Dermatol 2011 Sep 1; 10 (9): 1059–61Google Scholar
  139. 139.
    Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet 2007; 46 (8): 697–712PubMedGoogle Scholar
  140. 140.
    Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978 Apr; 21 (4): 535–8Google Scholar
  141. 141.
    Gettler S, Rothe M, Grin C, et al. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003; 4 (9): 597–608PubMedGoogle Scholar
  142. 142.
    Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based onmore than 350 patients. J Am Acad Dermatol 2005 Aug; 53 (2): 273–83Google Scholar
  143. 143.
    Elgart G, Stover P, Larson K, et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. J Am Acad Dermatol 1991 Jan; 24 (1): 83–6Google Scholar
  144. 144.
    Friedman S, Marion JF, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001 Feb; 7 (1): 1–7Google Scholar
  145. 145.
    Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J. Am Acad Dermatol 2010 Dec; 63 (6): 949–72; quiz 973-974Google Scholar
  146. 146.
    Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006 Apr; 55 (4): 505–9Google Scholar
  147. 147.
    Jacob SE, Weisman RS, Kerdel FA. Pyoderma gangrenosum: rebel without a cure? Int J Dermatol 2008 Feb; 47 (2): 192–4Google Scholar
  148. 148.
    Foss CE, Clark AR, Inabinet R, et al. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008 Aug; 22 (8): 943–9Google Scholar
  149. 149.
    Gulliver W. Successful treatment of recalcitrant pyoderma gangrenosumwith Raptiva. Poster presented at the 16th Congress of the European Academy of Dermatology and Venereology; 2007 May 16; ViennaGoogle Scholar
  150. 150.
    Woodson J. Use of efalizumab for the successful treatment of chronic recalcitrant pyoderma gangrenosum. Poster presented at the 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)Google Scholar
  151. 151.
    Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011 Oct; 147 (10): 1203–5Google Scholar
  152. 152.
    Schmidt C, Wittig BM, Moser C, et al. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn’s disease. Aliment Pharmacol Ther 2006 Jul 15; 24 (2): 343–50Google Scholar
  153. 153.
    Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma gangrenosum. J Dermatolog Treat 2004 Sep; 15 (5): 303–7Google Scholar
  154. 154.
    Rustin MH, Gilkes JJ, Robinson TW. Pyoderma gangrenosum associated with Behçet’s disease: treatment with thalidomide. J Am Acad Dermatol 1990 Nov; 23 (5 Pt 1): 941–4Google Scholar
  155. 155.
    Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000 Aug; 75 (8): 842–4Google Scholar
  156. 156.
    Zonana-Nacach A, Jiménez-Balderas FJ, Martínez-Osuna P, et al. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: report of 2 cases and review of the literature. J Rheumatol 1994 Jul; 21 (7): 1352–6Google Scholar
  157. 157.
    Callen JP, Case JD, Sager D. Chlorambucil: an effective corticosteroidsparing therapy for pyoderma gangrenosum. J Am Acad Dermatol 1989 Sep; 21 (3 Pt 1): 515–9Google Scholar
  158. 158.
    Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, et al. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial. J Rheumatol 1997 Apr; 24 (4): 689–93Google Scholar
  159. 159.
    de Zwaan SE, Iland HJ, Damian DL. Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. Australas J Dermatol 2009 Feb; 50 (1): 56–9Google Scholar
  160. 160.
    Hagman JH, Carrozzo AM, Campione E, et al. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001 Mar; 12 (1): 19–22Google Scholar
  161. 161.
    Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial 2007 Oct; 11 (5): 387–90Google Scholar
  162. 162.
    Seishima M, Mizutani Y, Shibuya Y, et al. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial 2007 Jun; 11 (3): 177–82PubMedGoogle Scholar
  163. 163.
    Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase- 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010 Feb; 159 (4): 842–55Google Scholar
  164. 164.
    McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010; 12 (3): R107, 1–11Google Scholar
  165. 165.
    Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-armpilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008 May; 24 (5): 1529–38Google Scholar
  166. 166.
    Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007 Nov; 33 (4): 787–802, viGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations